Amylx Pharmaceuticals Inc vs Booz Allen Hamilton Holding Corporation — how do they compare? Amylx Pharmaceuticals Inc trades at $23.96 (market cap $2.64B), while Booz Allen Hamilton Holding Corporation trades at $78.32 (market cap $9.45B). The key difference: Booz Allen Hamilton Holding Corporation is far larger — about 3.6× Amylx Pharmaceuticals Inc's market cap, and Booz Allen Hamilton Holding Corporation pays a 3% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | BAH | |
|---|---|---|
Market Cap | $2.64B | $9.45B |
Sector | Health | Industrials |
52-Week High | $24.19 | $111.63 |
52-Week Low | $7.82 | $59.71 |
Enterprise Value | $2.39B | $13.07B |
Dividend Yield | — | 3% |
Trailing returns across standard periods
Latest headlines on both assets
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.
Read more on BAH →